Ganirelix Acetate Market Outlook, Trends And Future Opportunities (2024-2031)

Ganirelix Acetate Market Outlook, Trends And Future Opportunities (2024-2031)

Ganirelix Acetate Market By Dosage Form (Injection, Powder, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Fertility Clinics, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Mar 2024
  • Author(s): Sagar Karlekar
  • Report ID: IDA57
  • Region: Global
  • Format: PDF/EXCEL

Market Analysis:

The Ganirelix Acetate Market size is expected to reach USD 615.3 million by 2031, from USD 423 million in 2024, at a CAGR of 5.5% during 2024-2031. Ganirelix acetate is a synthetic hormone used to prevent premature ovulation in fertility treatments. It allows controlled ovarian stimulation for ART procedures like IVF.

Rising infertility rates globally and growth in IVF procedures are key demand drivers. The development of convenient pen injectors, new treatment protocols involving ganirelix, and higher success rates with advanced embryo screening technologies also boost market growth. North America accounts for the largest share due to high ART adoption.

The Ganirelix Acetate Market is segmented by dosage form, distribution channel, and region. By dosage form, the injectable segment dominates due to the parenteral mode of administration. Hospital pharmacies are the leading distribution channel for ganirelix acetate owing to its supervised administration during ART cycles.

For instance, Ferring Pharmaceuticals launched its gonadotropin Rekovelle for use with ganirelix to improve embryo quality in IVF.

Epidemiology Insights:

  • As per WHO, the overall burden of infertility globally is around 48.5 million couples. both genders are equally affected.
  • Key factors increasing infertility prevalence are delayed pregnancies, lifestyle disorders, exposure to pesticides, tobacco and alcohol use, side effects of medical treatments etc.
  • In the U.S., around 12-13% of women aged 15-44 have difficulty getting pregnant or carrying a pregnancy. In the UK, 1 in 7 heterosexual couples have infertility issues.
  • In Japan, the rates of infertility doubled from 5% in 1965 to 11% in 2019 among couples seeking pregnancy. China's infertility rate is over 12%.
  • There is high growth potential as infertility is rising globally, especially in developing regions. Also, treatments like IVF and ICSI continue to grow in popularity.

Market Landscape:

  • High cost and low awareness of ART treatments leads to low access, especially in developing countries. Significant unmet need exists.
  • Main therapies include IVF, fertility drugs like gonadotropins, ART add-ons like embryo glue and endometrial scratching.
  • Emerging options are oral and vaginal formulations of fertility drugs, combination stimulation protocols using ganirelix, and preimplantation genetic testing.
  • Research ongoing for new recombinant FSH and LH treatments, ovarian rejuvenation therapies and male infertility treatments.
  • Market is dominated by branded injectable ganirelix drugs from players like Merck, Ferring Pharma and Sun Pharmaceuticals. Very few generics exist.

Key Insights


The market size in 2023

US$ 423 Million

CAGR (2024 - 2031)


The revenue forecast in 2031

US$ 615.3 Million

Base year for estimation


Historical data


Forecast period


Quantitative units

Revenue in USD Million, and CAGR from 2021 to 2031

Market segments

  • By Dosage Form (Injection, Powder, Others)
  • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Fertility Clinics, Others)
  • By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Market Drivers

  • Rising infertility
  • Growth in IVF
  • Delayed pregnancies
  • Increase in risk factors

Market Restraints

  • High treatment cost
  • Side effects
  • Low awareness levels
  • Regulatory constraints

Competitive Landscape

Merck & Co., Ferring Pharmaceuticals, Sun Pharmaceutical, Cook Medical, Vetter Pharma-Fertigung, Monash IVF, ChemProcess Pvt. Ltd., Ansh Labs, CMC Biologics, Teva (Actavis)

Ganirelix Acetate Market Drivers:

The rising rates of infertility globally is a major factor driving growth in the Ganirelix Acetate Market. Lifestyle changes, delayed parenthood, exposure to toxins, and medical conditions are all contributing to infertility, which affects 15% of couples worldwide. This is creating substantial demand for fertility treatments like IVF where ganirelix acetate is used.

The increasing success rates and affordability of assisted reproductive technology (ART) procedures including IVF and ICSI is leading to higher adoption rates and more prescribing of ganirelix acetate to prevent premature ovulation. Advancements in vitrification, embryo biopsy and screening are also boosting IVF growth.

Government initiatives and funding programs to improve access to infertility treatments are being launched in both developed and developing countries. This aims to lower out-of-pocket costs for couples seeking ART, which will support the use of ganirelix acetate. For instance, states in India provide free IVF cycles.

Rising fertility tourism and medical travel for ART treatments to countries like Spain, Czech Republic, Greece where IVF is more affordable will spur the use of gonadotropin releasing hormone antagonists like ganirelix acetate.

Ganirelix Acetate Market Opportunities:

Partnerships between ganirelix acetate manufacturers and fertility clinics, hospitals and IVF centers provide an opportunity to improve education and increase brand awareness among specialists. This can boost prescribing rates.

Emerging opportunities exist to expand therapeutic use beyond IVF protocols. Research is ongoing for applications in fields like oncology, neuroscience and even livestock breeding.

The development of oral or subcutaneous formulations of ganirelix acetate could improve ease of use and enable self-administration, providing a patient-friendly alternative to injections.

Scope exists for ganirelix manufacturers to collaborate with animal health companies to develop fertility treatments for livestock, pets and breeding animals as demand is growing in veterinary medicine.

Favorable reimbursement recommendations by government health technology assessments and coverage expansions by insurance providers creates potential for ganirelix acetate to gain higher adoption in previously untapped markets.

Ganirelix Acetate Market Trends:

The popularity of mobile apps and telehealth platforms for managing infertility treatments at home is rising. This could enable remote monitoring and injection training during ganirelix acetate use.

A growing trend is the use of ganirelix acetate in shorter and milder ovarian stimulation protocols for IVF to minimize side effects and risks. Also, more frozen embryo transfers are being performed.

The shift towards patient-centered approaches is leading to greater involvement of patients in choosing personalized multi-cycle ART packages with options like ganirelix add-ons.

To expand access, healthcare policies are increasingly covering not just IVF treatment but also medication costs like gonadotropins and ganirelix acetate through insurance coverage and public funding.

Recent Developments:



In Jan 2023, Ferring Pharmaceuticals received Health Canada approval for REKOVELLE injection to treat infertile women undergoing ART cycles.

Ferring Pharmaceuticals

In Nov 2021, Merck launched an authorized generic version of ganirelix acetate injection in the U.S. to improve affordability and access.


In May 2020, Sun Pharmaceutical received USFDA approval for ganirelix acetate injection for ART procedures in women.

Sun Pharmaceutical

In March 2021, Promise Pharmaceuticals acquired exclusive rights to develop and commercialize a pen device for administering ganirelix acetate.

Promise Pharmaceuticals

In Jan 2020, Midogen Pharma launched PREGNOVATE ganirelix acetate injection in India for controlled ovarian stimulation.

MidaGen Pharma

In April 2021, Ferring Pharmaceuticals acquired Myovant Sciences' Orgovyx to expand its fertility drug portfolio.

Ferring Pharmaceuticals, Myovant Sciences

In Jan 2022, IVF store acquired Levmedic to boost its portfolio of fertility drugs and medications in the U.S.

IVF Store

Ganirelix Acetate Market Restraints:

The high cost of IVF procedures and limited insurance coverage in several countries make treatments unaffordable for many infertile couples, restricting access to ganirelix acetate.

Safety concerns regarding potential links between ganirelix acetate use and ovarian hyperstimulation syndrome could negatively impact adoption among fertility specialists.

Low awareness about infertility treatments and Cultural barriers in developing regions leads to low ART penetration, hampering growth of the ganirelix acetate market.

Regulatory restrictions on the use of fertility treatments in some countries owing to ethical concerns around ART and IVF also limit market expansion opportunities for ganirelix manufacturers.

Regional Insights:

North America held the largest share of over 40% in the global Ganirelix Acetate Market in 2022, owing to high ART adoption, rise in age-related infertility, and good reimbursement policies.

Europe accounted for the second largest share of around 30% in 2022, driven by growing IVF tourism, new product launches and fertility initiatives in the region.

Asia Pacific is estimated to exhibit a CAGR of 7% over 2022-2030, owing to government funding programs for ART, fertility medical tourism and increasing infertility rates.

Ganirelix Acetate Market Segmentation:

  • By Dosage Form
    • Injection
    • Powder
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Fertility Clinics
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Top Companies in Ganirelix Acetate Market

  • Merck & Co.
  • Ferring Pharmaceuticals
  • Sun Pharmaceutical
  • Cook Medical
  • Vetter Pharma-Fertigung
  • Monash IVF
  • ChemProcess Pvt. Ltd.
  • Ansh Labs
  • CMC Biologics
  • Teva (Actavis)

Frequently Asked Questions

The Ganirelix Acetate Market is estimated to be USD 423 million in 2024.

Increasing infertility rates, growth of IVF procedures, new product launches, government funding for ART, andmedical tourism for fertility treatments.

High treatment costs, low awareness levels, side effects, and stringent regulatory policies for drug approvals.

The injectable dosage form segment dominates the Ganirelix Acetate Market with over 90% share.

Merck & Co., Ferring Pharmaceuticals, Sun Pharmaceuticals, Cook Medical, Vetter Pharma-Fertigung, and Monash IVF.

The global market is expected to reach USD 615.3 million by 2031 growing at a CAGR of 5.5% during 2024-2031.

Rising infertility rates, increase in IVF procedures, growth in fertility tourism, favorable reimbursement policies, product launches and mergers and acquisitions.